Morocco’s SOTHEMA is preparing to expand its pharmaceutical footprint with a potential acquisition of assets tied to the well-known erectile dysfunction drug Cialis. The deal, still awaiting regulatory approval, would give the Casablanca-based company rights to products marketed under the Cialis brand by U.S. pharmaceutical giant Eli Lilly and Company.
SOTHEMA, officially registered in Casablanca under number 35631, operates out of the Bouskoura industrial zone and focuses on manufacturing and distributing pharmaceutical products. If approved, the acquisition would mark a significant step forward for the Moroccan firm, boosting its portfolio in a high-demand therapeutic area with strong global recognition.
Eli Lilly, headquartered in Indianapolis, Indiana, is a major player in the global pharmaceutical industry. The company is involved in every stage of drug development, from early research to commercial distribution, and has a broad range of therapeutic specialties.
Importantly, the proposed transaction is limited to asset acquisition—it does not involve the purchase of any legal entity. Authorities have been formally notified, but the deal cannot proceed without their green light.
